Lonsec re-vamps iRate platform



Financial advisers will now be able to generate quicker and more in-depth financial analysis, after Lonsec announced the launch of research and reporting capability and tools platform, iRate.
In response to rapid developments in technology and increased competition across the finance sector, Lonsec Research chief executive, Matt Olsen, said that the enhanced iRate platform would take things back to basics.
"Despite new pressures, advisers must remain focused on the fundamentals of financial advice provision, on delivering outcomes related to client objectives," he said.
"Can they adapt the wealth of market data and information available to them in a way that is meaningful for individual clients?"
Olsen said that it was vital that platforms continued to evolve their adviser tools at the same pace as technology; iRate's new features are set to offer user-defined product asset classes, in line with the industry shift to transition to customer-centric providers.
"iRate will now offer time-series portfolios, allowing users to analyse a portfolio's performance where changes have been made to the holdings or asset allocation over time, as well as create user-defined product asset classes," he said.
"iRate enables users to create and analyse equity-only model portfolios, with fully integrated equity research. iRate also allows users to import and export portfolios easily."
Recommended for you
With the final tally for FY25 now confirmed, how many advisers left during the financial year and how does it compare to the previous year?
HUB24 has appointed Matt Willis from Vanguard as an executive general manager of platform growth to strengthen the platform’s relationships with industry stakeholders.
Investment manager Drummond Capital Partners has announced a raft of adviser-focused updates, including a practice growth division, relaunched manager research capabilities, and a passive model portfolio suite.
When it comes to M&A activity, the share of financial buyers such as private equity firms in Australia fell from 67 per cent to 12 per cent in the last financial year.